Rhonda Fleming
Infectious Disease · El Paso, TXNPI 1376590067
Payments from drug & device makers
Across 133 payments — averaging $78.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Viiv Healthcare Company$1K
- Smith+Nephew$420
- Organogenesis Inc.$248
- Melinta Therapeutics, LLC$220
- Insmed, Inc.$206
- plus $881 from 12 others
What the payments were for
- Speaking & faculty fees$4,92547%
- Travel & lodging$1,81717%
- Food & beverage$3,48533%
- Education$2683%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $7,397 |
| Viiv Healthcare Company | 26 | $1,123 |
| Smith+Nephew | 22 | $420 |
| Organogenesis Inc. | 3 | $248 |
| Melinta Therapeutics, LLC | 2 | $220 |
| Insmed, Inc. | 10 | $206 |
| Astellas Pharma US Inc | 2 | $134 |
| AstraZeneca | 1 | $123 |
| Osiris Therapeutics Inc. | 1 | $120 |
| Merck | 2 | $118 |
| Solventum Corporation | 1 | $100 |
| Janssen Products, LP | 1 | $99 |
| Johnson & Johnson | 3 | $71 |
| Cardiovascular Systems Inc. | 1 | $51 |
| La Jolla Pharmaceutical Company | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $14 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVYCAZ$6,683
- CABENUVA$496
- APRETUDE$249
- Apligraf$125
- Dermagraft$125
- Puraply/Affinity/NuTech$125
- FARXIGA$123
- Stravix$120
- Grafix$120
- GrafixPL$120
- Santyl$117
- Iodosorb$117
- Baxdela$112
- Rezzayo$108
- Allevyn Life$103
- PICO$103
- COLLAGENASE SANTYL$103
- ACTICOAT$103
- PIFELTRO$102
- DOVATO$101
How this compares
$10,495 in reported general payments places this provider in the 80th percentile of 576 infectious disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 30 | $123,141 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 24 | $111,184 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 25 | $101,364 |
| CabenuvaCabotegravir/Rilpivirine | 11 | $77,803 |
| DovatoDolutegravir Sodium/Lamivudine | 11 | $33,263 |
| Daptomycin | 41 | $14,964 |
| CefoxitinCefoxitin Sodium | 41 | $12,829 |
| ErtapenemErtapenem Sodium | 30 | $10,795 |
| Cefepime Hcl | 27 | $4,249 |
| Vancomycin Hcl | 24 | $2,604 |
| Methenamine Hippurate | 36 | $2,450 |
| Meropenem | 13 | $2,371 |
| Tolterodine Tartrate ErTolterodine Tartrate | 24 | $1,874 |
| Moxifloxacin Hcl | 12 | $1,227 |
| Fluconazole | 30 | $1,099 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTriumeq, Cabenuva, Dovato | $1,123 | $212,43147 claims |
| GileadBiktarvy | $13 | $123,14130 claims |
| Janssen Products, LPSymtuza | $99 | $111,18424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 576 infectious disease providers in Texas.
Other infectious disease in El Paso
- Ogechika AlozieEl Paso$2.5M
- Suresh AntonyEl Paso$84K
- Gene VoskuhlSherman$69.5M
- Mezgebe BerheDallas$11M
- Eleftherios MylonakisHouston$6.4M
- Mamta JainDallas$3.7M
- Cheryl McDonaldFort Worth$3.1M
- Roberto ArduinoHouston$2.1M
- Issam RaadHouston$2M
- Joseph GatheHouston$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.